Ftse Mib
32.946,62
0,86%
DAX
18.096,02
0,42%
S&P 500
5.431,60
-0,04%
NASDAQ
17.688,88
0,12%
Bitcoin
65.997,50
-0,96%
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Merus NV (MRUS) Merus NV (MRUS) Notizie

MRUS

Merus NV (MRUS)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:MRUS
DataOraFonteTitoloSimboloCompagnia
12/06/202423:02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MRUSMerus NV
03/06/202420:30GlobeNewswire Inc.Merus’ MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual MeetingNASDAQ:MRUSMerus NV
02/06/202418:30GlobeNewswire Inc.Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual MeetingNASDAQ:MRUSMerus NV
30/05/202423:21Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:MRUSMerus NV
30/05/202403:30GlobeNewswire Inc.Merus Announces Pricing of Upsized Public Offering of Common SharesNASDAQ:MRUSMerus NV
29/05/202414:00GlobeNewswire Inc.Merus to Participate in a Fireside Chat at the Jefferies Global Healthcare ConferenceNASDAQ:MRUSMerus NV
28/05/202422:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MRUSMerus NV
28/05/202422:01GlobeNewswire Inc.Merus N.V. Announces Proposed Public Offering of Common SharesNASDAQ:MRUSMerus NV
28/05/202413:00GlobeNewswire Inc.Merus’ Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and Favorable Safety Profile in 1L r/m HNSCCNASDAQ:MRUSMerus NV
23/05/202423:00GlobeNewswire Inc.Merus Announces Publication of an Abstract on Petosemtamab with Pembrolizumab as 1L treatment of r/m HNSCC at the 2024 ASCO® Annual MeetingNASDAQ:MRUSMerus NV
13/05/202414:00GlobeNewswire Inc.Petosemtamab granted Breakthrough Therapy Designation by the U.S. FDANASDAQ:MRUSMerus NV
10/05/202422:33Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:MRUSMerus NV
09/05/202422:30Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:MRUSMerus NV
08/05/202422:15GlobeNewswire Inc.Merus Announces Financial Results for the First Quarter 2024 and Provides Business UpdateNASDAQ:MRUSMerus NV
06/05/202422:05GlobeNewswire Inc.Merus Announces U.S. FDA Acceptance and Priority Review of Biologics License Application for Zeno for the Treatment of NRG1+ NSCLC and PDACNASDAQ:MRUSMerus NV
08/04/202418:00GlobeNewswire Inc.Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024NASDAQ:MRUSMerus NV
03/04/202414:00GlobeNewswire Inc.Merus to Participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:MRUSMerus NV
06/03/202414:00Business WireGilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell EngagersNASDAQ:MRUSMerus NV
05/03/202422:30GlobeNewswire Inc.Merus Announces Publication of an Abstract for Presentation at the AACR Annual Meeting 2024: Zeno is effective in cancer models with high NRG1 expressionNASDAQ:MRUSMerus NV
04/03/202414:00GlobeNewswire Inc.Merus to Participate in a Fireside Chat at the Leerink Partners Global Biopharma ConferenceNASDAQ:MRUSMerus NV
28/02/202422:55Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:MRUSMerus NV
28/02/202422:15GlobeNewswire Inc.Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business UpdateNASDAQ:MRUSMerus NV
14/02/202422:05Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:MRUSMerus NV
31/01/202414:00GlobeNewswire Inc.Merus to Participate in Upcoming Investor ConferencesNASDAQ:MRUSMerus NV
16/12/202301:29Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:MRUSMerus NV
03/12/202302:40GlobeNewswire Inc.Merus Presents Interim Data on MCLA-129 at ESMO Asia Congress 2023NASDAQ:MRUSMerus NV
26/11/202317:05GlobeNewswire Inc.Merus Announces Publication of Abstracts on MCLA-129 for Presentation at ESMO Asia Congress 2023NASDAQ:MRUSMerus NV
02/11/202321:12GlobeNewswire Inc.Merus Announces Financial Results for the Third Quarter 2023 and Provides Business UpdateNASDAQ:MRUSMerus NV
02/11/202321:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MRUSMerus NV
23/10/202313:30GlobeNewswire Inc.Merus’ Zeno Interim Data Continues to Demonstrate Robust and Durable Responses in NRG1+ CancerNASDAQ:MRUSMerus NV
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:MRUS

La tua Cronologia

BIT
LDO
Leonardo
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
ENI
Eni
BIT
TIT
Telecom Italia
BIT
SPM
Saipem
BIT
MONC
Moncler
BIT
G
Generali
BIT
ERG
ERG
BIT
TEN
Tenaris
BIT
UNI
Unipol Gruppo
BIT
HER
Hera
BIT
IVG
Iveco Group NV
BIT
FBK
Finecobank
BIT
SRG
Snam
BIT
AZM
Azimut Hldg
BIT
DNR
Industrie De Nora
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network